Novo Nordisk A S annual shareholders’ equity
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Shareholders’ Equity Growth & History (NVO)
Novo Nordisk A S's shareholders’ equity was kr194.05B for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | kr194.05B | kr50.56B | +35.24% |
| 2024 | 2024-12-31 | kr143.49B | kr36.92B | +34.65% |
| 2023 | 2023-12-31 | kr106.56B | kr23.07B | +27.64% |
| 2022 | 2022-12-31 | kr83.49B | kr12.74B | +18.01% |
| 2021 | 2021-12-31 | kr70.75B | kr7.42B | +11.72% |
| 2020 | 2020-12-31 | kr63.33B | kr5.73B | +9.95% |
| 2019 | 2019-12-31 | kr57.59B | — | — |
Novo Nordisk A S quarterly shareholders’ equity
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | kr221.28B | kr53.21B | +31.66% |
| Q1 2026 | 2026-03-31 | kr203.06B | — | — |
| Q4 2025 | 2025-12-31 | kr194.05B | kr50.56B | +35.24% |
| Q3 2025 | 2025-09-30 | kr169.90B | — | — |
| Q2 2025 | 2025-06-30 | kr168.07B | — | — |
| Q4 2024 | 2024-12-31 | kr143.49B | kr36.92B | +34.65% |
| Q4 2023 | 2023-12-31 | kr106.56B | kr23.07B | +27.64% |
| Q4 2022 | 2022-12-31 | kr83.49B | kr12.74B | +18.01% |
| Q4 2021 | 2021-12-31 | kr70.75B | — | — |
Novo Nordisk A S shareholders’ equity trends
Over the last five fiscal years, Novo Nordisk A S's shareholders’ equity increased from kr63.33B to kr194.05B, a change of kr130.72B. The latest reported quarter, Q2 2026, shows kr221.28B.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...